Antiviral effects of artesunate on polyomavirus bk replication in primary human kidney cells

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 279-289

  Sharma, Biswa Nath ^a,b   Marschall, Manfred ^c   Henriksen, Stian ^a   Rinaldo, Christine Hanssen ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CELL DNA; CYTOSTATIC AGENT; DEOXYURIDINE; LACTATE DEHYDROGENASE; MESSENGER RNA; PROTEIN VP1; VIRUS LARGE T ANTIGEN;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CONTROLLED STUDY; DNA REPLICATION; DRUG EFFECT; EPITHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE REPLICATION; HOST CELL; HUMAN; HUMAN CELL; KIDNEY CELL; METABOLIC ACTIVITY ASSAY; POLYOMA VIRUS; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RENAL PROXIMAL TUBULAR EPITHELIAL CELL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ARTEMISININS; BK VIRUS; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; VIRUS REPLICATION;

EID: 84891535998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01800-13     Document Type: Article

References (54)

1. Hirsch HH. 2010. Polyoma and papilloma virus infections after hemato-poietic stem cell or solid organ transplantation, p 465-482. In Bowden P, Ljungman P, Snydman DR (ed), Transplant infections, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Hirsch HH, Steiger J. 2003. Polyomavirus BK. Lancet Infect. Dis. 3:611- 623. http://dx.doi.org/10.1016/S1473-3099(03)00770-9.
3. Funk GA, Gosert R, Comoli P, Ginevri F, Hirsch HH. 2008. Polyoma-virus BK replication dynamics in vivo and in silico to predict cytopathol-ogy and viral clearance in kidney transplants. Am. J. Transplant. 8:2368- 2377. http://dx.doi.org/10.1111/j.1600-6143.2008.02402.x.
4. Nickeleit V, Hirsch HH, Binet IF, Gudat F, Prince O, Dalquen P, Thiel G, Mihatsch MJ. 1999. Polyomavirus infection of renal allograft recipients: From latent infection to manifest disease. J. Am. Soc. Nephrol. 10: 1080-1089.
5. Hirsch HH. 2002. Polyomavirus BK nephropathy: A (re-)emerging complication in renal transplantation. Am. J. Transplant. 2:25-30. http://dx.doi.org/10.1034/j.1600-6143.2002.020106.x.
6. Azzi A, Cesaro S, Laszlo D, Zakrzewska K, Ciappi S, de Santis R, Fanci R, Pesavento G, Calore E, Bosi A. 1999. Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J. Clin. Virol. 14:79 - 86. http://dx.doi.org/10.1016/S1386-6532(99)00055-4.
7. Binet I, Nickeleit V, Hirsch HH. 2000. Polyomavirus infection in transplant recipients. Curr. Opin. Organ Transplant. 5:210-216. http://dx.doi.org/10.1097/00075200-200009000-00007.
8. Hirsch HH, Randhawa P. 2009. BK virus in solid organ transplant recipients. Am.J.Transplant. 9(Suppl 4):S136-S146. http://dx.doi.org/10.1111/j. 1600-6143.2009.02904.x.
9. Krisl JC, Taber DJ, Pilch N, Chavin K, Bratton C, Thomas B, Mc-Gillicuddy J, Baliga P. 2012. Leflunomide efficacy and pharmacodynam-ics for the treatment of BK viral infection. Clin. J. Am. Soc. Nephrol. 7:1003-1009. http://dx.doi.org/10.2215/CJN.12531211.
10. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. 2010. Treatment of polyomavirus infection in kidney transplant recipients: A systematic review. Transplantation 89:1057-1070. http://dx.doi.org/10.1097/TP. 0b013e3181d0e15e.
11. Rinaldo CH, Hirsch HH. 2007. Antivirals for the treatment of polyoma-virus BK replication. Expert Rev. Anti Infect. Ther. 5:105-115. http://dx.doi.org/10.1586/14787210.5.1.105.
12. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH. 2008. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am. J. Transplant. 8:1413-1422. http://dx.doi.org/10.1111/j.1600-6143.2008.02269.x.
13. Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. 2010. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J. Virol. 84:2150 -2156. http://dx.doi.org/10.1128/JVI.01737- 09.
14. Klayman DL. 1985. Qinghaosu (artemisinin): An antimalarial drug from China. Science 228:1049 -1055. http://dx.doi.org/10.1126/science.3887571.
15. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ. 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): An open-label, randomised trial. Lancet 376:1647-1657. http://dx.doi.org/10.1016/S0140-6736(10)61924-1.
16. Dondorp A, Nosten F, Stepniewska K, Day N, White N. 2005. Artesu-nate versus quinine for treatment of severe falciparum malaria: A randomised trial. Lancet 366:717-725. http://dx.doi.org/10.1016/S0140 -6736(05)67176-0.
17. Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES. 2002. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. 80:233-242. http://dx.doi.org/10.1007/s00109- 001-0300-8.
18. Kaptein SJ, Efferth T, Leis M, Rechter S, Auerochs S, Kalmer M, Bruggeman CA, Vink C, Stamminger T, Marschall M. 2006. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 69:60-69. http://dx.doi.org/10.1016/j.antiviral.2005.10.003.
19. Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stam-minger T, Caplan O, Saleh N, Efferth T, Marschall M, Wolf DG. 2008. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46:1455-1457. http://dx.doi.org/10.1086/587106.
20. Wolf DG, Shimoni A, Resnick IB, Stamminger T, Neumann AU, Chou S, Efferth T, Caplan O, Rose J, Nagler A, Marschall M. 2011. Human cytomegalovirus kinetics following institution of artesunate after hemato-poietic stem cell transplantation. Antiviral Res. 90:183-186. http://dx.doi.org/10.1016/j. antiviral.2011.03.184.
21. Lau PK, Woods ML, Ratanjee SK, John GT. 2011. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin. Infect. Dis. 52:279. http://dx.doi.org/10.1093/cid/ciq050.
22. Sellar RS, Ward KN, Thomson KJ, Peggs KS. 2012. Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT. Bone Marrow Transplant. 47:1482-1483. http://dx.doi.org/10.1038/bmt.2012. 46.
23. Hakacova N, Klingel K, Kandolf R, Engdahl E, Fogdell-Hahn A, Higgins T. 2013. First therapeutic use of artesunate in treatment of human her-pesvirus 6B myocarditisin achild.J. Clin. Virol. 57:157-160. http://dx.doi.org/10.1016/j. jcv.2013.02.005.
24. Auerochs S, Korn K, Marschall M. 2011. A reporter system for Epstein-Barr virus (EBV) lytic replication: Anti-EBV activity of the broad anti-herpesviral drug artesunate. J. Virol. Methods 173:334-339. http://dx.doi.org/10.1016/j. jviromet.2011.03.005.
25. Milbradt J, Auerochs S, Korn K, Marschall M. 2009. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J. Clin. Virol. 46:24-28. http://dx.doi.org/10.1016/j.jcv.2009. 05.017.
26. Romero MR, Efferth T, Serrano MA, Castano B, Macias RI, Briz O, Marin JJ. 2005. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res. 68:75- 83. http://dx.doi.org/10.1016/j.antiviral.2005.07.005.
27. Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. 2008. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47:804-811. http://dx.doi.org/10.1086/591195.
28. Romero MR, Serrano MA, Vallejo M, Efferth T, Alvarez M, Marin JJ. 2006. Antiviral effectofartemisinin from Artemisia annua againstamodel member of the Flaviviridae family, the bovine viral diarrhoea virus (BVDV). Planta Med. 72:1169-1174. http://dx.doi.org/10.1055/s-2006 -947198.
29. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. 2011. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malaria J. 10:263. http://dx.doi.org/10.1186/1475-2875- 10-263.
30. Olsen GH, Hirsch HH, Rinaldo CH. 2009. Functional analysis of polyo-mavirus BK non-coding control region quasispecies from kidney transplant recipients. J. Med. Virol. 81:1959-1967. http://dx.doi.org/10.1002/jmv.21605.
31. Rinaldo CH, Gosert R, Bernhoff E, Finstad S, Hirsch HH. 2010. 1-O-Hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavi-rus BK replication in primary human renal tubular epithelial cells. Anti-microb. Agents Chemother. 54:4714-4722. http://dx.doi.org/10.1128/AAC.00974-10.
32. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. 2011. Fluo-roquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res. 92:115-123. http://dx.doi.org/10.1016/j. antiviral.2011.07.012.
33. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2( - delta delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
34. Hirsch HH, Mohaupt M, Klimkait T. 2001. Prospective monitoring of BK virus load after discontinuing sirolimus treatmentin a renal transplant patient with BK virus nephropathy. J. Infect. Dis. 184:1494-1496. http://dx.doi.org/10. 1086/324425.
35. Randhawa PS, Vats A, Zygmunt D, Swalsky P, Scantlebury V, Shapiro R, Finkelstein S. 2002. Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy. Transplantation 74:485-488. http://dx.doi.org/10.1097/00007890-200208270-00009.
36. Rinaldo CH, Myhre MR, Alstad H, Nilssen O, Traavik T. 2003. Human polyomavirus BK (BKV) transiently transforms and persistently infects cultured osteosarcoma cells. Virus Res. 93:181-187. http://dx.doi.org/10.1016/S0168- 1702(03)00096-0.
37. Hey AW, Johnsen JI, Johansen B, Traavik T. 1994. A two fusion partner system for raising antibodies against small immunogens expressed in bacteria. J. Immunol. Methods 173:149-156. http://dx.doi.org/10.1016/0022-1759(94)90294-1.
38. Rinaldo CH, Traavik T, Hey A. 1998. The agnogene of the human polyomavirus BK is expressed. J. Virol. 72:6233-6236.
39. Riss TL, Moravec RA. 2004. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev. Technol. 2:51-62. http://dx.doi.org/10.1089/154065804322966315.
40. Cuesta I, Nunez-Ramirez R, Scheres SH, Gai D, Chen XS, Fanning E, Carazo JM. 2010. Conformational rearrangements of SV40 large T antigen during early replication events. J. Mol. Biol. 397:1276-1286. http://dx.doi.org/10.1016/j. jmb.2010.02.042.
41. An P, Saenz Robles MT, Pipas JM. 2012. Large T antigens of polyoma-viruses: Amazing molecular machines. Annu. Rev. Microbiol. 66:213-236. http://dx.doi.org/10.1146/annurev-micro-092611-150154.
42. Cole CN. 1996. Polyomavirinae: The viruses and their replication, p 1997- 2025. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 3rd ed. Lippincott-Raven Press, Philadelphia, PA.
43. 1 cell cycle arrest and iron-mediated mito-chondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer Drugs 23:606 - 613. http://dx.doi.org/10.1097/CAD.0b013e328350e8ac.
44. Finaurini S, Basilico N, Corbett Y, D'Alessandro S, Parapini S, Olliaro P, Haynes RK, Taramelli D. 2012. Dihydroartemisinin inhibits the human erythroid cell differentiation by altering the cell cycle. Toxicology 300:57- 66. http://dx.doi.org/10.1016/j.tox.2012.05.024.
45. Li S, Xue F, Cheng Z, Yang X, Wang S, Geng F, Pan L. 2009. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int. J. Hematol. 90:513- 521. http://dx.doi.org/10.1007/s12185-009-0409-z.
46. Xu Q, Li ZX, Peng HQ, Sun ZW, Cheng RL, Ye ZM, Li WX. 2011. Artesunate inhibits growth and induces apoptosisin human osteosarcoma HOS cell line in vitro and in vivo. J. Zhejiang Univ. Sci. B 12:247-255. http://dx.doi.org/10. 1631/jzus.B1000373.
47. Jiang M, Zhao L, Gamez M, Imperiale MJ. 2012. Roles of ATM and ATR-mediated DNA damage responses during lytic BK polyomavirus infection. PLoS Pathog. 8:e1002898. http://dx.doi.org/10.1371/journal.ppat.1002898.
48. Chou S, Marousek G, Auerochs S, Stamminger T, Milbradt J, Marschall M. 2011. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res. 92:364 -368. http://dx.doi.org/10.1016/j.antiviral.2011.07.018.
49. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM. 2011. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: A randomized clinical trial. PLoS One 6:e19283. http://dx.doi.org/10.1371/journal.pone.0019283.
50. Efferth T, Kaina B. 2010. Toxicity of the antimalarial artemisinin and its derivatives. Crit. Rev. Toxicol. 40:405-421. http://dx.doi.org/10.3109/ 10408441003610571.
51. Schnepf N, Corvo J, Pors MJ, Mazeron MC. 2011. Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocy-toma cells. Antiviral Res. 89:186-188. http://dx.doi.org/10.1016/j.antiviral.2010.12.002.
52. Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, Morch K, Foroutan B, Suttorp N, Yurek S, Flick H. 2011. Intravenous artesunate for severe malaria in travelers, Europe. Emerg. Infect. Dis. 17: 771-777. http://dx.doi.org/10.3201/eid1705.101229.
53. Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, Weina PJ. 2009. Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: A phase I study. Am. J. Trop. Med. Hyg. 81:615-621. http://dx.doi.org/10.4269/ajtmh.2009.09-0150.
54. Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Melendez V, Smith B, Weina PJ. 2012. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study. Malaria J. 11:255. http://dx.doi.org/10.1186/1475-2875 -11-255.